A bioequivalence trial is a statistically based comparison of two form
ulations to demonstrate with a controlled consumer (patient) risk that
two formulated drug products are interchangeable. The basic assumptio
n underlying a bioequivalence trial is that essentially the same plasm
a time-course leads to essentially the same effect allowing two formul
ations to be interchanged, Bioequivalence is generally assessed using
kinetic end points and in practice, two formulations in which bioavail
ability parameters (rate and extent) differ by 20% or less, with a 90%
degree of confidence, are considered to be bioequivalent, In this rev
iew, the design and evaluation of bioequivalence studies are presented
with special attention given to scientific issues.